A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip
- Conditions
- Osteoarthritis of Hip
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 32
- Registration Number
- NCT06977568
- Locations
- 🇺🇸
Medical Pain Management Services PLLC, Albany, New York, United States
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
- Conditions
- Osteoarthritis (OA) of the Knee
- Interventions
- Biological: Enekinragene Inzadenovec (PCRX-201)Biological: Placebo
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 135
- Registration Number
- NCT06884865
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸Osteoporosis Medical Center, Beverly Hills, California, United States
🇺🇸Arrow Clinical Trials, Daytona Beach, Florida, United States
Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity
- Conditions
- Spasticity, Cerebral or Spinal Condition
- Interventions
- Device: sham iovera° system treatmentDevice: iovera° system
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 132
- Registration Number
- NCT06340451
- Locations
- 🇺🇸
Rancho Los Amigos National Rehabilitation Center, Downey, California, United States
🇺🇸Source Healthcare - Santa Monica, Santa Monica, California, United States
🇺🇸Nova Clinical Research, LLC, Bradenton, Florida, United States
Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06271265
- Locations
- 🇺🇸
Duke University Health System, Durham, North Carolina, United States
🇺🇸University of Oklahoma (OU) - Medical Center - The Children's Hospital, Oklahoma City, Oklahoma, United States
🇺🇸The University of Texas Health Science Center at Houston (UTHSC-H) - McGovern Medical School, Houston, Texas, United States
ZILRETTA in Subjects With Shoulder Osteoarthritis
- Conditions
- Glenohumeral Osteoarthritis
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 250
- Registration Number
- NCT06269705
- Locations
- 🇺🇸
Alabama Orthopaedic Center- Research, Vestavia Hills, Alabama, United States
🇺🇸Onyx Clinical Research, Surprise, Arizona, United States
🇺🇸Tucson Orthopaedic Institute (TOI) - East Office, Tucson, Arizona, United States
Innovations in Genicular Outcomes Registry
- Conditions
- Knee Osteoarthritis
- Interventions
- Procedure: Treatment for Knee OA
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 2000
- Registration Number
- NCT05495334
- Locations
- 🇺🇸
Orthopedic Education and Research Institute of So Ca (Hoag), Irvine, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸MidState Orthopedics and Sports Medicine, Alexandria, Louisiana, United States
Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 54
- Registration Number
- NCT05456490
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy
- Conditions
- BunionectomyHallux Valgus
- Interventions
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 185
- Registration Number
- NCT05157841
- Locations
- 🇺🇸
Lotus Clinical Research, Pasadena, California, United States
🇺🇸Midwest Clinical Research Center, Dayton, Ohio, United States
🇺🇸HD Research- First Surgical Hospital, Bellaire, Texas, United States
Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
- Conditions
- Knee OsteoarthritisPain Management
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 167
- Registration Number
- NCT05139030
- Locations
- 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Endeavor Clinical Trials, San Antonio, Texas, United States
🇺🇸Lotus Clinical Research, Pasadena, California, United States
Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 85
- Registration Number
- NCT04826328
- Locations
- 🇺🇸
Lotus Clinical Research, Huntington Hospital, Pasadena, California, United States